GlassScriptPhysician profile
Thomson Sam Varghese
NPI 1366852527
$2,410.55
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $255 · 2021: $145 · 2022: $677 · 2023: $689 · 2024: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $644.71 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $522.44 | 2022-2024 | Breztri, Tezspire, Fasenra |
| Insmed, INC. | $235.86 | 2020-2022 | |
| Mylan Specialty L.P. | $144.28 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.03 | 2022-2024 | Ofev |
| Regeneron Healthcare Solutions, INC. | $129.29 | 2021-2024 | Dupixent |
| United Therapeutics Corporation | $124.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.00 | 2024 | |
| Grifols USA, LLC | $114.15 | 2022-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $65.67 | 2022-2024 | Glassia |
| Alexion Pharmaceuticals, INC. | $57.79 | 2022 | |
| Mallinckrodt Hospital Products INC. | $33.26 | 2022-2023 | Acthar |
| Csl Behring | $21.14 | 2020 | |
| Abbvie INC. | $20.48 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.93 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomson Sam Varghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.